Drug news: EGP-467 expected to commence Phase III

In a news report on the results from the anterior uveitis study of this drug, they mentioned that it's expected to enter Phase III for the dry eye indication this quarter. (Phase II was completed last spring and this is the first news since that time.)

EyeGate Pharma Completes Phase II Study of EGP-437 in Patients With Anterior Uveitis

...In the second quarter of 2010, the Company plans to initiate a multi-center Phase III study in dry eye patients....